Trial designs used to study neuroprotective therapy in Parkinson's disease
Identifieur interne : 000E10 ( Main/Exploration ); précédent : 000E09; suivant : 000E11Trial designs used to study neuroprotective therapy in Parkinson's disease
Auteurs : Anthony E. Lang [Canada] ; Eldad Melamed [Israël] ; Werner Poewe [Autriche] ; Olivier Rascol [France]Source :
- Movement Disorders [ 0885-3185 ] ; 2013-01.
Abstract
There have been numerous trials conducted to evaluate putative disease‐modifying or neuroprotective treatments in Parkinson's disease. These trials have used several different study designs and outcome measures. Each of these has its own strengths and weaknesses. Confounding all studies is the potential symptomatic benefit that the treatment might have on the features of Parkinson's disease. In addition, patient‐related factors such as age of onset and the nature of the dominant symptoms may have important impacts that are often not addressed. Here we provide an overview of the various trial designs that have been used and emphasize the challenges faced in attempting to study neuroprotection in Parkinson's disease and the advances needed before this goal can be successfully achieved. © 2013 Movement Disorder Society
Url:
DOI: 10.1002/mds.24997
Affiliations:
- Autriche, Canada, France, Israël
- Midi-Pyrénées, Occitanie (région administrative), Tyrol (Land)
- Innsbruck, Toulouse
- Université de médecine d'Innsbruck
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001120
- to stream Istex, to step Curation: 001118
- to stream Istex, to step Checkpoint: 000017
- to stream Main, to step Merge: 000E38
- to stream Main, to step Curation: 000E10
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Trial designs used to study neuroprotective therapy in Parkinson's disease</title>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
</author>
<author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation><country>Autriche</country>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1F8441423F9E5A20B3681C5AA731F29E6D85371F</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1002/mds.24997</idno>
<idno type="url">https://api.istex.fr/document/1F8441423F9E5A20B3681C5AA731F29E6D85371F/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001120</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001120</idno>
<idno type="wicri:Area/Istex/Curation">001118</idno>
<idno type="wicri:Area/Istex/Checkpoint">000017</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000017</idno>
<idno type="wicri:doubleKey">0885-3185:2013:Lang A:trial:designs:used</idno>
<idno type="wicri:Area/Main/Merge">000E38</idno>
<idno type="wicri:Area/Main/Curation">000E10</idno>
<idno type="wicri:Area/Main/Exploration">000E10</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Trial designs used to study neuroprotective therapy in Parkinson's disease</title>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, Ontario, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Canada</country>
</affiliation>
</author>
<author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>The Norma and Alan Aufzien Chair for Resarch of Parkinson's Disease, Sackler School of Medicine, Tel Aviv University, Tel Aviv</wicri:regionArea>
<wicri:noRegion>Tel Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Innsbruck Medical University, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Investigation Center and Department of Clinical Pharmacology and Neurosciences, CIC9302 INSERM and UMR825, Toulouse University Hospital, University of Toulouse‐3, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov Disord</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Blackwell Publishing Ltd</publisher>
<date type="published" when="2013-01">2013-01</date>
<biblScope unit="volume">28</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="86">86</biblScope>
<biblScope unit="page" to="95">95</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">1F8441423F9E5A20B3681C5AA731F29E6D85371F</idno>
<idno type="DOI">10.1002/mds.24997</idno>
<idno type="ArticleID">MDS24997</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract">There have been numerous trials conducted to evaluate putative disease‐modifying or neuroprotective treatments in Parkinson's disease. These trials have used several different study designs and outcome measures. Each of these has its own strengths and weaknesses. Confounding all studies is the potential symptomatic benefit that the treatment might have on the features of Parkinson's disease. In addition, patient‐related factors such as age of onset and the nature of the dominant symptoms may have important impacts that are often not addressed. Here we provide an overview of the various trial designs that have been used and emphasize the challenges faced in attempting to study neuroprotection in Parkinson's disease and the advances needed before this goal can be successfully achieved. © 2013 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Autriche</li>
<li>Canada</li>
<li>France</li>
<li>Israël</li>
</country>
<region><li>Midi-Pyrénées</li>
<li>Occitanie (région administrative)</li>
<li>Tyrol (Land)</li>
</region>
<settlement><li>Innsbruck</li>
<li>Toulouse</li>
</settlement>
<orgName><li>Université de médecine d'Innsbruck</li>
</orgName>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
</noRegion>
<name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
</country>
<country name="Israël"><noRegion><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name>
</noRegion>
</country>
<country name="Autriche"><region name="Tyrol (Land)"><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
</region>
</country>
<country name="France"><region name="Occitanie (région administrative)"><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E10 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E10 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:1F8441423F9E5A20B3681C5AA731F29E6D85371F |texte= Trial designs used to study neuroprotective therapy in Parkinson's disease }}
This area was generated with Dilib version V0.6.29. |